The evaluation of metabolic syndrome in patients diagnosed with non-alcoholic fatty liver disease (NAFLD): a cross-sectional study of Iranian population

Sajjadi, Samaneh; Hejazi, Sepide; Akbari Rad, Mina; Khosravi, Ahmad; Firoozi, Abdollah; Jarrahi, Lida

doi:10.30483/rijm.2021.249754.0

The evaluation of metabolic syndrome in patients diagnosed with non-alcoholic fatty liver disease (NAFLD): a cross-sectional study of Iranian population

Document Type : Original Article

Authors

¹ Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

² Mashhad University of Medical Sciences, Mashhad, Iran

³ Department of Social Medicine, Faculty of Medicine, Mashhad University

10.30483/rijm.2021.249754.0

Abstract

Introduction:Our study is assessing the epidemiological aspects of nonalcoholic fatty liver disease (NAFLD) in Iranian population and evaluates the relationship between NAFLD and metabolic syndrome.

Methods and Materials:We conducted this cross-sectional study on 145 subjects who were diagnosed with NAFLD and referred to the Gastroenterology clinics of Ghaem Hospital, Mashhad, Iran in the year of 2013. Using ultrasonography method, we diagnosed NAFLD as a fatty liver manifestation in the absence of other liver complications. We used National Cholesterol Education Program Adult Treatment Panel III criteria (ATPIII) as a guideline to establish metabolic syndrome diagnosis.

Results: Metabolic syndrome had an overall prevalence of 49.7% among our subjects. The results showed no difference in mean AST and ALT levels between the groups of patients with and without metabolic syndrome. Our results were unable to maintain an association between our targeted liver enzymes (AST and ALT) and different features of metabolic syndrome. In multivariate linear regression models, the presence of metabolic syndrome was unable to predict AST (p=0.631, r2=0.002) or ALT (p=0.122, r2=0.017) abnormalities.

Conclusion: The present study has shown a high prevalence of metabolic syndrome in Iranian patients who diagnosed with NAFLD. Contrary to previous reports, despite the high prevalence of metabolic syndrome conditions in NAFLD patients, we found that the presence of metabolic syndrome had not increased the risk of NAFLD in the population undergone our study.

Keywords

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

1. Sonsuz A, Basaranoglu M, Ozbay G. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2000;95(5):1370-1. https://doi.org/10.1111/j.1572-0241.2000.02046.x PMid:10811364

2. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155-61. https://doi.org/10.1159/000282080 PMid:20460905

3. Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol. 2015;7(6):846-58. https://doi.org/10.4254/wjh.v7.i6.846 PMid:25937862 PMCid:PMC4411527

4. Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis. 2010;14(4):591-604. https://doi.org/10.1016/j.cld.2010.07.006 PMid:21055684

5. Pacifico L, Poggiogalle E, Cantisani V, Menichini G, Ricci P, Ferraro F, et al. Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J Hepatol. 2010;2(7):275-88. https://doi.org/10.4254/wjh.v2.i7.275 PMid:21161009 PMCid:PMC2998974

6. Sanyal AJ, American Gastroenterological A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705-25. https://doi.org/10.1053/gast.2002.36572 PMid:12404245

7. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59(4):859-71. https://doi.org/10.1016/j.jhep.2013.05.044 PMid:23751754

8. Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(22):6821-5. https://doi.org/10.3748/wjg.v20.i22.6821 PMid:24944472 PMCid:PMC4051921

9. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936-44. https://doi.org/10.1111/jgh.13264 PMid:26667191

10. Maheshwari A, Thuluvath PJ. Endocrine diseases and the liver. Clin Liver Dis. 2011;15(1):55-67. https://doi.org/10.1016/j.cld.2010.09.008 PMid:21111993

11. Caserta CA, Mele A, Surace P, Ferrigno L, Amante A, Messineo A, et al. Association of non-alcoholic fatty liver disease and cardiometabolic risk factors with early atherosclerosis in an adult population in Southern Italy. Ann Ist Super Sanita. 2017;53(1):77-81.

12. Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran. Iran J Public Health. 2014;43(9):1275-83.

13. Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, et al. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013;13(5):e9248. https://doi.org/10.5812/hepatmon.9248

14. Grundy SM, Hansen B, Smith SC, Jr., Cleeman JI, Kahn RA, American Heart A, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109(4):551-6. https://doi.org/10.1161/01.CIR.0000112379.88385.67 PMid:14757684

15. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92(9):3490-7. https://doi.org/10.1210/jc.2007-0482 PMid:17595248

16. Chen SH, He F, Zhou HL, Wu HR, Xia C, Li YM. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J Dig Dis. 2011;12(2):125-30. https://doi.org/10.1111/j.1751-2980.2011.00487.x PMid:21401898

17. Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, et al. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 2012;18(13):1508-16. https://doi.org/10.3748/wjg.v18.i13.1508 PMid:22509083 PMCid:PMC3319947

18. Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, Narayani, et al. Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome. J Assoc Physicians India. 2009;57:201-4.

19. Fattahi MR, Niknam R, Safarpour A, Sepehrimanesh M, Lotfi M. The Prevalence of Metabolic Syndrome In Non-alcoholic Fatty Liver Disease; A Population-Based Study. Middle East J Dig Dis. 2016;8(2):131-7. https://doi.org/10.15171/mejdd.2016.18 PMid:27252820 PMCid:PMC4885612

20. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43(3):508-14. https://doi.org/10.1016/j.jhep.2005.02.042 PMid:16006003

21. Hu X, Huang Y, Bao Z, Wang Y, Shi D, Liu F, et al. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol. 2012;12:123. https://doi.org/10.1186/1471-230X-12-123 PMid:22978800 PMCid:PMC3499402

22. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47(5):586-95. https://doi.org/10.1007/s00535-012-0533-z PMid:22328022

23. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-23. https://doi.org/10.1053/jhep.2003.50161 PMid:12668987

24. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007;11(1):105-17, ix. https://doi.org/10.1016/j.cld.2007.02.013 PMid:17544974

25. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18(6):353-8. https://doi.org/10.1016/S0261-5614(99)80015-6 PMid:10634920

26. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53(7):1020-3. https://doi.org/10.1136/gut.2003.027086 PMid:15194655 PMCid:PMC1774102

27. Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007;22(12):2118-23. https://doi.org/10.1111/j.1440-1746.2006.04698.x PMid:18031368

Razavi International Journal of Medicine

Article View: 181
PDF Download: 116

The evaluation of metabolic syndrome in patients diagnosed with non-alcoholic fatty liver disease (NAFLD): a cross-sectional study of Iranian population

References

Volume 9, Issue 3
July 2021
Pages 73-78

Files

Share

How to cite

Statistics

The evaluation of metabolic syndrome in patients diagnosed with non-alcoholic fatty liver disease (NAFLD): a cross-sectional study of Iranian population

References

Volume 9, Issue 3July 2021Pages 73-78

Files

Share

How to cite

Statistics

Volume 9, Issue 3
July 2021
Pages 73-78